Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for ELVN

Stock NameEnliven Therapeutics Inc.
TickerELVN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS29337E1029

Show aggregate ELVN holdings

News associated with ELVN

Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) PT at $41.20
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) has earned a consensus recommendation of “Buy” from the five ratings firms that are currently covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have updated their coverage on the stock in the […] - 2025-08-08 02:42:46
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $281,500.00 in Stock
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CEO Samuel Kintz sold 12,500 shares of the company’s stock in a transaction dated Thursday, July 17th. The stock was sold at an average price of $22.52, for a total transaction of $281,500.00. Following the transaction, the chief executive officer owned 940,392 shares in the company, valued […] - 2025-07-22 07:14:55
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 1,000 Shares
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CFO Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $22.66, for a total transaction of $22,660.00. Following the transaction, the chief financial officer directly owned 23,000 shares of the company’s […] - 2025-07-15 06:21:06
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Recommendation of “Buy” from Brokerages
Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) have received an average recommendation of “Buy” from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued a […] - 2025-07-11 05:23:02
Enliven Therapeutics (NASDAQ:ELVN) Trading 7.9% Higher Following Analyst Upgrade
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s stock price was up 7.9% on Wednesday after HC Wainwright raised their price target on the stock from $40.00 to $48.00. HC Wainwright currently has a buy rating on the stock. Enliven Therapeutics traded as high as $20.74 and last traded at $21.20. Approximately 171,529 shares traded […] - 2025-07-04 02:24:46
Exchange Traded Concepts LLC Reduces Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Exchange Traded Concepts LLC decreased its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 19.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 6,055 shares of the company’s stock after selling 1,428 shares during the period. Exchange Traded Concepts LLC’s holdings in Enliven Therapeutics were worth $119,000 as of its most […] - 2025-06-24 04:38:52
Rhumbline Advisers Increases Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Rhumbline Advisers raised its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 4.9% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 52,502 shares of the company’s stock after acquiring an additional 2,466 shares during the period. Rhumbline Advisers’ holdings in Enliven Therapeutics were worth $1,033,000 […] - 2025-06-20 04:22:47
Robert W. Baird Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) had its target price lifted by equities research analysts at Robert W. Baird from $40.00 to $52.00 in a report issued on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s price target indicates a potential upside of 138.53% from the stock’s […] - 2025-06-18 03:08:46
Enliven Therapeutics (NASDAQ:ELVN) Coverage Initiated at The Goldman Sachs Group
Investment analysts at The Goldman Sachs Group assumed coverage on shares of Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) in a report released on Monday, MarketBeat Ratings reports. The firm set a “buy” rating and a $37.00 price target on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 69.72% from […] - 2025-06-18 03:08:45
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up Following Analyst Upgrade
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s stock price gapped up prior to trading on Monday after Robert W. Baird raised their price target on the stock from $40.00 to $52.00. The stock had previously closed at $21.91, but opened at $23.38. Robert W. Baird currently has an outperform rating on the stock. Enliven […] - 2025-06-17 02:08:49
Two Sigma Investments LP Decreases Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Two Sigma Investments LP lowered its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 33.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 14,620 shares of the company’s stock after selling 7,460 shares during the quarter. Two Sigma Investments LP’s holdings in Enliven Therapeutics were worth $329,000 as of its […] - 2025-06-11 04:30:51
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 3.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,036 shares of the company’s stock after purchasing an additional 718 shares during the […] - 2025-05-30 04:55:02
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Recommendation of “Buy” by Brokerages
Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) have been assigned an average rating of “Buy” from the five analysts that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month […] - 2025-05-27 05:26:58
Voya Investment Management LLC Decreases Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Voya Investment Management LLC trimmed its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 8.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,702 shares of the company’s stock after selling 945 shares during the quarter. Voya […] - 2025-05-13 05:22:51
Marshall Wace LLP Has $931,000 Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Marshall Wace LLP cut its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 70.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 41,382 shares of the company’s stock after selling 96,624 shares during the quarter. Marshall Wace LLP’s holdings in Enliven Therapeutics were worth $931,000 at the end […] - 2025-05-01 04:50:53
ExodusPoint Capital Management LP Acquires New Shares in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
ExodusPoint Capital Management LP bought a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 8,900 shares of the company’s stock, valued at approximately $200,000. Other hedge funds have also added to or reduced […] - 2025-04-15 04:39:25
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by Fmr LLC
Fmr LLC grew its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,495,871 shares of the company’s stock after acquiring an additional 199,692 shares during the quarter. Fmr LLC owned about 0.13% […] - 2025-04-14 05:48:47
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock Holdings Lowered by Corebridge Financial Inc.
Corebridge Financial Inc. cut its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 7.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,500 shares of the company’s stock after selling 1,321 shares during the quarter. […] - 2025-04-10 04:49:04
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 4.9% Following Insider Selling
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s share price traded down 4.9% during mid-day trading on Tuesday following insider selling activity. The stock traded as low as $18.61 and last traded at $18.73. 40,658 shares were traded during mid-day trading, a decline of 85% from the average session volume of 275,231 shares. The stock […] - 2025-04-03 02:44:44
Tuesday's ETF Movers: BLOK, IHE
In trading on Tuesday, the Amplify Transformational Data Sharing ETF is outperforming other ETFs, up about 1.8% on the day. Components of that ETF showing particular strength include shares of Core Scientific, up about 8.1% and shares of Applied Digital, up about 6.6% on the da - 2025-04-01 13:04:57
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst Says
Enliven Therapeutics (NASDAQ:ELVN – Free Report) had its price objective lifted by HC Wainwright from $37.00 to $39.00 in a research report sent to investors on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. Separately, BTIG Research began coverage on Enliven Therapeutics in a report on Friday, December 13th. They set […] - 2025-03-24 04:13:03

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) ELVN holdings

DateNumber of ELVN Shares HeldBase Market Value of ELVN SharesLocal Market Value of ELVN SharesChange in ELVN Shares HeldChange in ELVN Base ValueCurrent Price per ELVN Share HeldPrevious Price per ELVN Share Held
2025-11-11 (Tuesday)38,003USD 746,379ELVN holding increased by 35343USD 746,3790USD 35,343 USD 19.64 USD 18.71
2025-11-10 (Monday)38,003ELVN holding increased by 98USD 711,036ELVN holding increased by 42771USD 711,03698USD 42,771 USD 18.71 USD 17.63
2025-11-07 (Friday)37,905USD 668,265ELVN holding decreased by -25397USD 668,2650USD -25,397 USD 17.63 USD 18.3
2025-11-06 (Thursday)37,905ELVN holding increased by 98USD 693,662ELVN holding decreased by -5768USD 693,66298USD -5,768 USD 18.3 USD 18.5
2025-11-05 (Wednesday)37,807USD 699,430ELVN holding decreased by -19281USD 699,4300USD -19,281 USD 18.5 USD 19.01
2025-11-04 (Tuesday)37,807ELVN holding increased by 98USD 718,711ELVN holding decreased by -35469USD 718,71198USD -35,469 USD 19.01 USD 20
2025-11-03 (Monday)37,709USD 754,180ELVN holding decreased by -128965USD 754,1800USD -128,965 USD 20 USD 23.42
2025-10-31 (Friday)37,709USD 883,145ELVN holding decreased by -20740USD 883,1450USD -20,740 USD 23.42 USD 23.97
2025-10-30 (Thursday)37,709ELVN holding increased by 490USD 903,885ELVN holding increased by 60875USD 903,885490USD 60,875 USD 23.97 USD 22.65
2025-10-29 (Wednesday)37,219ELVN holding increased by 196USD 843,010ELVN holding increased by 45164USD 843,010196USD 45,164 USD 22.65 USD 21.55
2025-10-28 (Tuesday)37,023USD 797,846ELVN holding increased by 5554USD 797,8460USD 5,554 USD 21.55 USD 21.4
2025-10-27 (Monday)37,023USD 792,292ELVN holding increased by 29248USD 792,2920USD 29,248 USD 21.4 USD 20.61
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ELVN by Blackrock for IE00BYXG2H39

Show aggregate share trades of ELVN

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY9818.95517.820 17.933USD 1,757 21.20
2025-11-06BUY9818.56017.810 17.885USD 1,753 21.24
2025-11-04BUY9820.23018.630 18.790USD 1,841 21.26
2025-10-30BUY49024.03022.400 22.563USD 11,056 21.24
2025-10-29BUY19622.65022.880 22.857USD 4,480 21.24
2025-10-22SELL-39220.49021.190 21.120USD -8,279 21.25 Profit of 49 on sale
2025-10-20BUY19622.12022.360 22.336USD 4,378 21.24
2025-10-17BUY48921.41021.990 21.932USD 10,725 21.24
2025-10-15BUY77621.73021.750 21.748USD 16,876 21.24
2025-10-03BUY68619.61020.193 20.135USD 13,812 21.25
2025-10-02BUY9819.92020.090 20.073USD 1,967 21.26
2025-09-30BUY19620.47020.900 20.857USD 4,088 21.27
2025-09-26BUY19620.01020.550 20.496USD 4,017 21.29
2025-09-25BUY19618.57019.085 19.033USD 3,731 21.30
2025-09-24BUY4,39919.20019.510 19.479USD 85,688 21.31
2025-09-18BUY8619.92519.990 19.983USD 1,719 21.32
2025-09-17BUY25819.02019.500 19.452USD 5,019 21.34
2025-08-20SELL-34019.66020.030 19.993USD -6,798 21.38 Profit of 471 on sale
2025-07-30BUY33619.32020.415 20.306USD 6,823 21.45
2025-07-17SELL-17023.34023.710 23.673USD -4,024 21.43 Loss of -380 on sale
2025-07-11SELL-68022.45023.210 23.134USD -15,731 21.42 Loss of -1,168 on sale
2025-07-07BUY25519.59021.175 21.016USD 5,359 21.43
2025-07-02BUY4,67520.64021.285 21.220USD 99,206 21.44
2025-06-20BUY1,21421.30022.070 21.993USD 26,700 21.44
2025-06-11BUY16219.60521.900 21.670USD 3,511 21.45
2025-06-10BUY16221.70021.935 21.911USD 3,550 21.44
2025-06-04SELL-8122.29022.520 22.497USD -1,822 21.45 Loss of -85 on sale
2025-04-23BUY8117.77019.610 19.426USD 1,574 22.41
2025-04-10SELL-64814.91015.720 15.639USD -10,134 23.01 Profit of 4,773 on sale
2025-04-08SELL-8115.82018.760 18.466USD -1,496 23.16 Profit of 380 on sale
2025-04-07SELL-8117.87019.690 19.508USD -1,580 23.22 Profit of 301 on sale
2025-04-04SELL-40518.69020.040 19.905USD -8,062 23.28 Profit of 1,366 on sale
2025-04-01BUY33618.88019.625 19.550USD 6,569 23.37
2025-03-31SELL-24319.68021.160 21.012USD -5,106 23.42 Profit of 584 on sale
2025-03-21BUY1,16421.08021.408 21.375USD 24,881 23.58
2025-03-14SELL-1,24820.74022.210 22.063USD -27,535 23.78 Profit of 2,141 on sale
2025-03-07SELL-15621.00022.290 22.161USD -3,457 24.02 Profit of 289 on sale
2025-03-04SELL-7819.92020.020 20.010USD -1,561 24.16 Profit of 324 on sale
2025-02-25BUY15620.13021.530 21.390USD 3,337 24.51
2025-02-19SELL-7721.90022.065 22.049USD -1,698 24.72 Profit of 206 on sale
2025-02-13BUY23121.50022.910 22.769USD 5,260 24.96
2025-02-12BUY7722.05022.080 22.077USD 1,700 25.02
2025-02-11BUY30821.41021.820 21.779USD 6,708 25.10
2024-12-30SELL-1,72322.39022.775 22.736USD -39,175 26.53 Profit of 6,538 on sale
2024-11-18SELL-1,21524.90024.925 24.922USD -30,281 28.50 Profit of 4,347 on sale
2024-11-08SELL-8128.96029.400 29.356USD -2,378 28.56 Loss of -64 on sale
2024-10-21SELL-8128.87029.110 29.086USD -2,356 0.00 Loss of -2,356 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ELVN

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19255,5122,440367,30069.6%
2025-09-18205,7420372,47655.2%
2025-09-17162,9261,997258,66063.0%
2025-09-16210,6140354,40959.4%
2025-09-15158,96815285,25855.7%
2025-09-12150,9770331,82845.5%
2025-09-1196,0600385,68624.9%
2025-09-1047,9496151,23231.7%
2025-09-09131,8830239,21455.1%
2025-09-08196,3068,811347,78556.4%
2025-09-0563,2560131,30948.2%
2025-09-0478,4350146,46853.6%
2025-09-03105,0050189,63455.4%
2025-09-0292,210308154,10759.8%
2025-08-29152,705246324,86747.0%
2025-08-28113,3720320,88435.3%
2025-08-27114,8532,880257,35044.6%
2025-08-2636,9370145,78925.3%
2025-08-25150,6680277,23854.3%
2025-08-22164,5360493,35133.4%
2025-08-21208,2231,982440,28247.3%
2025-08-2069,5641,006132,98752.3%
2025-08-1942,0583,41078,03253.9%
2025-08-1852,7763,411113,03046.7%
2025-08-1549,843607137,04436.4%
2025-08-1460,7670121,82349.9%
2025-08-1377,8340145,51653.5%
2025-08-1276,4110165,02446.3%
2025-08-1149,374080,19161.6%
2025-08-08148,399100336,54044.1%
2025-08-0775,0442,200122,75161.1%
2025-08-06123,11720222,05555.4%
2025-08-05103,5010245,37542.2%
2025-08-0436,934099,77437.0%
2025-08-01100,8650290,37934.7%
2025-07-3172,6650189,29338.4%
2025-07-3083,0290128,49264.6%
2025-07-2941,5270133,28631.2%
2025-07-2844,8201,104199,29022.5%
2025-07-2538,438675,23751.1%
2025-07-2472,74728125,30058.1%
2025-07-2327,864077,64335.9%
2025-07-2250,0680117,13742.7%
2025-07-2163,6827,051239,26926.6%
2025-07-1839,727258109,46436.3%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.